Combination Bleomycin, Ifosfamide, and Cisplatin Chemotherapy in Cervical Cancer
- 1 March 1989
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 81 (5) , 359-361
- https://doi.org/10.1093/jnci/81.5.359
Abstract
We report a phase II study of bleomycin, ifosfamide, and cisplatin (BIP) in cervical cancer. Our aims were to assess response rate, toxicity, and survival in women treated with this combination. Among 49 patients, 34 objective responses (69%) were seen, with 10 complete responses (20%). Toxic effects were assessed in 186 treatment cycles. All patients had alopecia and nausea and vomiting. Other effects included myelosuppression, infection, reduction in renal function, and disturbance of consciousness. These data indicate that BIP is highly active against advanced and recurrent cervical cancer. [J Natl Cancer Inst 81:359–361, 1989]This publication has 5 references indexed in Scilit:
- Young age as a prognostic factor in cervical cancer: analysis of population based data from 10 022 casesBMJ, 1988
- A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervixCancer Chemotherapy and Pharmacology, 1986
- Prediction of Ifosfamide/Mesna associated encephalopathyEuropean Journal of Cancer and Clinical Oncology, 1986
- PHASE-II STUDY OF IFOSFAMIDE IN CERVICAL-CANCER1986
- Cervical carcinoma: A drug-responsive tumor—experience with combined cisplatin, vinblastine, and bleomycin therapyGynecologic Oncology, 1983